AIMS: To characterize the impact of potent CYP3A4 inhibition and induction on lapatinib pharmacokinetics. METHODS: Two studies were conducted in healthy subjects. One study examined the effect of ketoconazole 200 mg b.i.d. for 7 days on a single 100-mg dose of lapatinib in 22 healthy subjects. The other study examined the effect of carbamazepine titrated up to 200 mg b.i.d. over 20 days on a single 250-mg dose of lapatinib in 24 healthy subjects. RESULTS:Ketoconazole altered lapatinib AUC, C(max) and half-life, with geometric mean [95% confidence interval (CI)] increases of 3.57-fold (3.07, 4.15), 2.14-fold (1.74, 2.64) and 1.66-fold (1.50, 1.84), respectively, but had no effect on absorption rate. Carbamazepine altered lapatinib AUC, C(max) and absorption rate, with geometric mean (95% CI) decreases of 72% (68, 77), 59% (49, 66) and 28% (4, 46), respectively, but had no effect on half-life. CONCLUSIONS: Systemic exposure to lapatinib was significantly altered by potent inhibition and induction of CYP3A4. Dose adjustments may be required when lapatinib is administered with orally administered drugs that potently alter the activity of this enzyme.
RCT Entities:
AIMS: To characterize the impact of potent CYP3A4 inhibition and induction on lapatinib pharmacokinetics. METHODS: Two studies were conducted in healthy subjects. One study examined the effect of ketoconazole 200 mg b.i.d. for 7 days on a single 100-mg dose of lapatinib in 22 healthy subjects. The other study examined the effect of carbamazepine titrated up to 200 mg b.i.d. over 20 days on a single 250-mg dose of lapatinib in 24 healthy subjects. RESULTS:Ketoconazole altered lapatinib AUC, C(max) and half-life, with geometric mean [95% confidence interval (CI)] increases of 3.57-fold (3.07, 4.15), 2.14-fold (1.74, 2.64) and 1.66-fold (1.50, 1.84), respectively, but had no effect on absorption rate. Carbamazepine altered lapatinib AUC, C(max) and absorption rate, with geometric mean (95% CI) decreases of 72% (68, 77), 59% (49, 66) and 28% (4, 46), respectively, but had no effect on half-life. CONCLUSIONS: Systemic exposure to lapatinib was significantly altered by potent inhibition and induction of CYP3A4. Dose adjustments may be required when lapatinib is administered with orally administered drugs that potently alter the activity of this enzyme.
Authors: R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson Journal: Pharm Res Date: 1999-03 Impact factor: 4.200
Authors: Aimee K Bence; Eric B Anderson; Maqbool A Halepota; Michael A Doukas; Phillip A DeSimone; George A Davis; Deborah A Smith; Kevin M Koch; Andrew G Stead; Steve Mangum; Carolyn J Bowen; Neil L Spector; Showchien Hsieh; Val R Adams Journal: Invest New Drugs Date: 2005-01 Impact factor: 3.850
Authors: Jarkko Rautio; Joan E Humphreys; Lindsey O Webster; Anand Balakrishnan; John P Keogh; Jeevan R Kunta; Cosette J Serabjit-Singh; Joseph W Polli Journal: Drug Metab Dispos Date: 2006-02-02 Impact factor: 3.922
Authors: Florian Läpple; Oliver von Richter; Martin F Fromm; Tanja Richter; Klaus P Thon; Hermann Wisser; Ernst-Ulrich Griese; Michel Eichelbaum; Kari T Kivistö Journal: Pharmacogenetics Date: 2003-09
Authors: E G Schuetz; J D Schuetz; S C Strom; M T Thompson; R A Fisher; D T Molowa; D Li; P S Guzelian Journal: Hepatology Date: 1993-11 Impact factor: 17.425
Authors: Joanna K Towles; Rebecca N Clark; Michelle D Wahlin; Vinita Uttamsingh; Allan E Rettie; Klarissa D Jackson Journal: Drug Metab Dispos Date: 2016-07-22 Impact factor: 3.922